{"entity":{"id":"snv1521","kind":"drug","name":"SNV1521","aka":[],"tldr":"SNV1521 is an experimental pill being studied to block a DNA-repair enzyme in cancer cells.","summary":"Synnovation describes SNV1521 as a PARP1-selective inhibitor. The linked registry records distinguish recruiting, closed, and discontinued studies; those states do not establish comparative efficacy or approval.","status":"phase-1","asOf":"2026-10-06","links":[{"label":"ClinicalTrials.gov NCT07756281","url":"https://clinicaltrials.gov/study/NCT07756281"},{"label":"ClinicalTrials.gov NCT06220864","url":"https://clinicaltrials.gov/study/NCT06220864"},{"label":"Primary publication or sponsor source","url":"https://www.synnovationtx.com/news/parp1-fip-pressrelease"}],"tags":[],"related":[],"cancers":["pancreatic"],"sections":[],"technologies":[],"targets":["parp"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct07756281","nct06220864"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"modality":"Small-molecule PARP1 inhibitor","mechanism":"Synnovation describes SNV1521 as a PARP1-selective inhibitor.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/snv1521/","neighbours":{"cancer":[{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/"}],"target":[{"id":"parp","kind":"target","name":"PARP","route":"/targets/parp/"}],"trial":[{"id":"nct07756281","kind":"trial","name":"First in Human Study of SNV1521 With a RAS Inhibitor for People With Advanced Pancreatic Cancer","route":"/trials/nct07756281/"},{"id":"nct06220864","kind":"trial","name":"SNV1521 in Participants With Advanced Solid Tumors","route":"/trials/nct06220864/"}]}}